Excited to share our publication of T-DXd vs. T-DM1 in pts with brain 🧠 mets from DB-03.

⭐️ PFS 15 months w/T-DXd vs. 3 months w/ T-DM1

Trastuzumab deruxtecan vs trastuzumab emtansine in brain metastases in DESTINY-Breast03 trial - ESMO Open esmoopen.com/article/S2059-…

T-DXd is the premier ADC for the treatment of pts with HER2+ MBC BrMs.

The analysis underscores the pressing need to investigate T-DXd in HER2-low BrMs, active HER2+ BrMs across solid tumors, and LMD.
We suggest default inclusion of pts with BrMs into clinical trials of ADCs.

This week we lost swaggsheila, a fierce advocate for the entire metastatic community. To know her was to love her: her smile lit up the room, and her positivity was felt throughout. Sheila was a GRASP mentor since our first in-person at SABCS2019, and her loss is felt deeply.

This opinion piece is now open-access!

Thank you to MBC Alliance!

Look who’s being highlighted in the latest edition of FDA Oncology’ Project Community newsletter!

The amazing Barbara Segarra!

Rea Blakey met a jewel of an advocate and recognized it right away!

Patients should be the ones to say if their treatment is 'WELL TOLERATED' & discussions about dose reductions need to be part of #sharedDecisionMaking .
❤️ this patient-centered survey & the discussion raised about the tradeoffs in #MBC #BreastCancer #BCSM
ascopubs.org/doi/pdf/10.120…

#BCSM

**US based MBC patients**

Diagnosed with HER2+ (positive) or HER2+/ER+ (triple positive) stage IV #metastaticbreastcancer ?

Have you considered stopping HER2 therapy?

Please share your experience by completing this anonymous survey @ redcap.link/TREAT_HER2

Please RT

Anne dedicated the last decade of her life, living w MBC, to advocacy, & made an impact that will remain - & grow! - for years to come.

What an honor to have been by her side from the start of the Patient-Centered Dosing Initiative, & be leading it now.

therightdose.org/in-memoriam

Thank you to The ICR, and special thanks to all my colleagues and trainees for perseverance, support, and passion, especially HoadleyLab and the two remarkable trainees-turned-stars, Holly Tovey and Milana Bergamino Sirven

Do you @Wordle? It’s a great way to keep your brain active, and ( #spoileralert ) today we thank The New York Times for giving us some recognition! 🟩

Great opportunity for #brainmets patients to learn about current & promising treatments from an excellent panel of experts! #bcsm

Attn all interested clinicians/scientists: Save the date for 2nd Annual #BrainMets Advanced Therapeutics Symposium: * 3/7/24 * virtual * free. Stay tuned for more on the engaging, interactive program. #btsm #lcsm #bcsm Neurosurgery at Memorial Sloan Kettering MSK Department of Medicine Memorial Sloan Kettering Radiation Oncology MSK CME

Looking for a clinical trial? BreastCancerTrials.org has launched Trial Alerts – a new feature on Metastatic Trial Search that include emails with new #MBC trials posted w/in the last week that match your profile.

Visit metastatictrialsearch.org to create a profile and receive alerts! #bcsm

The GRASP Poster Walkthrough at #LatinoCancer2024 was a huge success!

Here Julia Maués is with Barbara Segarra & Sandi Stanford, the creators of the Latino patient advocate training, and Marcela Mazo MD, whose FLEX study poster was recognized with the GRASP Advocate Choice Award.

GRASP our prtner in the Latino Cancer Patient Advocate Training Program! Thanks Julia Maués Christine Hodgdon

Excited for the keynote lineup at the MSK #BrainMets symposium on March 7: Drs Alexander Drilon, Nicole Willmarth and Julia Maues 🦸‍♂️🦸‍♀️🦸‍♀️ bit.ly/BrainMets2024 - register today (complementary) for insights into the next wave of innovation #medtwitter #btsm #lcsm #bcsm

Take a moment to read about the amazing advocate & all-around wonderful human being that is Yvonne Florence on the NCCS - National Coalition for Cancer Survivorship blog. Her advocacy impacts so many people & organizations, and we at GRASP are lucky to be among them.

canceradvocacy.org/together-we-ca…

Thank you very much Bravo-Cordero Lab for inviting me to speak at the The Tisch Cancer Institute seminar series. A very memorable ❄️🌨️ storm and grateful for the chance present our work UTSW Simmons Cancer Center on natural killer cells and innate barriers to metastasis !!

Exploring the latest in metastasis research, especially brain mets, on our website through hopefully easy-to-understand summaries. Feedback welcome (DM please) to enhance the platform! #CancerResearch #BrainMets

dvresearchinsights.com/lay-summaries/

One of the most critical features of novel ADCs is their emerging intracranial activity. Few treatments in oncology allow to achieve >50% intracranial response rates, with durable (PFS 15 months!!) efficacy. Interesting meta-analysis - follow ESMO Open for more! 👇